Marcellus Investment Managers filed a police complaint against ex-CFO Pankaj Harish Gupta for diverting Rs 1.18 crore for personal use. The firm reassures clients their investments remain unaffected. Gupta admitted misappropriation, while Marcellus cooperates with authorities, emphasizing transparency, governance, and business continuity. Client assets are safeguarded.Read More

The Indian equity market ended a three-week winning streak as Nifty50 slipped 2.6%, pressured by global trade tensions, H-1B visa concerns, and persistent foreign outflows. Time-based technical signals indicate potential intraday volatility, emphasizing cautious trading and disciplined risk management for short-term traders amid fluctuating support and resistance levels.Read More

After a year where gold and silver dazzled investors, Axis MF’s Equity Head Shreyash Devalkar believes 2026 could mark a turning point. With earnings recovery, sectoral rotation and supportive macros lining up, he argues Nifty may finally outshine precious metals, setting the stage for a classic mean reversion trade.Read More

Post ContentRead More

Precision components maker Indo MIM has filed preliminary papers with markets regulator Sebi to raise funds through an initial public offering (IPO) comprising a fresh issue of equity shares worth Rs 1,000 crore.Read More

Tata Capital plans India’s largest 2025 IPO of Rs 17,200 crore on October 6. Proceeds will boost Tier-1 capital, supporting lending growth. Grey market trades at Rs 29; valuation ~$18 billion.Read More

The combined market valuation of the top-10 most valued firms eroded by Rs 2,99,661.36 crore last week, in line with a bearish trend in equities, with IT bellwether Tata Consultancy Services taking the biggest hit.Read More

Spirit maker Alcobrew Distilleries India Ltd has filed draft papers with capital markets regulator Sebi to seek its approval to raise funds through an initial public offering (IPO).Read More

Sun Pharma faces potential impact from the US 100% tariff on patented drugs, which could reduce FY26–27 earnings by 8–10%. Generic drugs remain exempt. The company’s innovative portfolio, strong cash position, and mitigation options support steady revenue growth, maintaining HSBC’s Buy rating with Rs 1,850 target.Read More

The latest Trend Tracker shows Nifty falling 2.7% due to visa fee hikes and pharma sector tariffs, settling below 24,700. Analysts expect weak sentiment with stock-specific action. ETMarkets lists five picks — Hindustan Copper, NLC India, Usha Martin, Jindal Saw, Capri Global Capital — offering up to 28% upside in the near term.Read More